You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
From changes in trial enrollment to increased flexibility, clinical trials in precision oncology and other fields are feeling the brunt of the ongoing COVID-19 pandemic.
Using data from over 500 CAR cell clinical trials, researchers hope to improve patient-trial matching and future immunotherapy designs.
Researchers at BostonGene and Weill Cornell Medicine hope their approach may provide a more complete and precise characterization of diffuse large B-cell lymphomas.
The patient-derived organoids, though, couldn't predict response to a 5-fluorouracil plus oxaliplatin regimen, underscoring more research is needed before clinical use.
The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.
A New York Genome Consortium-led team plans retrospective and prospective analyses on very rare cancers in the hopes of improving treatment options available for patients.
The assay monitors mutations across a patient's genome and matches them to mutations found in a patient's resected tumor and in DNA in the bloodstream.